Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Choroidal neovascularization (CNV) is the most common vision-threatening macular complication in pathologic myopia (PM) being detectable in 4-11% of the affected eyes. Treatment of PM-related CNV is still controversial. Intravitreal injections of antivascular endothelial growth factor molecules are able to inhibit the vascular endothelial growth factor isoforms and have shown promise in the treatment of myopic CNV. The present review describes the beneficial effects of this approach both for subfoveal and juxtafoveal CNV. However, considering the lack of randomized clinical trials and the relatively short follow-up in most of the studies, a multicentric clinical trial should be necessary to validate the positive results in the long term.

Original languageEnglish
Title of host publicationAnti-VEGF
PublisherS. Karger AG
Pages73-83
Number of pages11
Volume46
ISBN (Print)9783805595308, 9783805595292
DOIs
Publication statusPublished - Aug 13 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia'. Together they form a unique fingerprint.

Cite this